What this trial means for you
This study is opening soon at 1 US site. It's studying Semaglutide 1.0 mg, Semaglutide 2.0 mg for alcohol use disorder (aud), obesity (bmi equal to or >30).
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Male and females ages 18-60 and BMI in 30-49.9 kg/m2; * regular weekly alcohol use (at least 3X/week) prior to admission; * must meet current DSM-V criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-V; * Good health as verified by screening and physical examination; * Able to read English and complete study evaluation; * Able to provide informed written and verbal consent. Exclusion Criteria: * Meet current criteria for moderate to severe substance use disorders from abuse of any another psychoactive substance, excluding nicotine; * Current use of opiates; * Current use of psychiatric medications, including benzodiazepine-based sedatives/anxiolytics and anticonvulsants, non SSRI antidepressants, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), acamprosate, naltrexone, antabuse, baclofen, varenicline; * Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania); * Endocrine or immune disorders, including diagnosis of diabetes (T2D or T1D) by American Diabetes Association (ADA) criteria or a history of HgbA1c \>6.5% and on current medications for T2D treatment; * Significant underlying medical conditions, including history of pancreatitis, acute kidney injury, medullary thyroid cancer, or MEN syndrome, as well as other cerebral, renal, thyroid or cardiac pathology that would preclude study participation; * Current use of any anti-obesity medications; * Prior history of bariatric surgery or current intragastric balloon; * Current participation in structured meal replacement or weight loss program; * Weight loss of \>=10% over the preceding 6 months; * Women who are pregnant, nursing or refuse use of reliable form of birth control.
Study sites by state
Connecticut
- Yale Stress Center, New Haven
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.